Imatinib mesylate in the treatment of hematologic malignancies

The treatment of hematologic malignancies has been based for many years on chemotherapy and possibly, for the more aggressive forms, stem cell transplantation. In 2001, the signal transduction inhibitor 571 (STI571, imatinib mesylate) was reported to have striking effects in chronic myeloid leukaemia patients. Since then, imatinib became the first molecular-targeted agent approved for the treatment of human cancer and was later on demonstrated to be effective in other malignancies, such as Philadelphia positive acute lymphoid leukemia, hypereosinophilic syndromes, gastrointestinal stromal tumours and more recently, systemic mastocytosis and other myeloprolipherative disease-carrying platelet-derived growth factor receptor abnormalities. In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the abovementioned diseases.

[1]  P. Jacobs,et al.  A Possible Specific Chromosome Abnormality in Human Chronic Myeloid Leukæmia , 1960, Nature.

[2]  A. Rimm,et al.  BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKAEMIA IN FIRST AND SECOND REMISSION , 1987, The Lancet.

[3]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[4]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[5]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[6]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[7]  D. Metcalfe,et al.  The treatment of mastocytosis: an overview. , 1991, The Journal of investigative dermatology.

[8]  V. Najfeld,et al.  Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. , 1993, Leukemia.

[9]  D. Williams,et al.  Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. , 1993, The New England journal of medicine.

[10]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[11]  S. Galli,et al.  New concepts about the mast cell. , 1993, The New England journal of medicine.

[12]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[13]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[14]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[15]  J. Radich,et al.  Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.

[16]  J. Melo,et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.

[17]  J. Aster,et al.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.

[18]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[19]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[20]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  J. Griffin,et al.  ARG tyrosine kinase activity is inhibited by STI571. , 2001, Blood.

[22]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[23]  J. Radich.  Philadelphia chromosome-positive acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.

[24]  D. Fabbro,et al.  Imatinib: a selective tyrosine kinase inhibitor. , 2002, European journal of cancer.

[25]  B. Druker,et al.  Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[27]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[28]  D. Hoelzer,et al.  Recent approaches in acute lymphoblastic leukemia in adults. , 2000, Reviews in clinical and experimental hematology.

[29]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[30]  B. Druker,et al.  Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* , 2002, The Journal of Biological Chemistry.

[31]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[32]  H. Gschaidmeier,et al.  Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) , 2002, Leukemia.

[33]  H. Gschaidmeier,et al.  Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.

[34]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[35]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[36]  W. Hofmann,et al.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[38]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[39]  E. Baxter,et al.  Imatinib for systemic mast-cell disease , 2003, The Lancet.

[40]  Yoo-Jin Kim,et al.  Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2003, Blood.

[41]  Rocco Piazza,et al.  Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.

[42]  C. Peschel,et al.  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back , 2003, Leukemia.

[43]  Susan Branford,et al.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.

[44]  B. Druker,et al.  Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.

[45]  C. Perry,et al.  Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. , 2003, Drugs.

[46]  J. Esteve,et al.  Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate. , 2004 .

[47]  W. Hofmann,et al.  Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia , 2004, Leukemia & lymphoma.

[48]  M. Baccarani,et al.  The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. , 2004, Haematologica.

[49]  C. Preudhomme,et al.  Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft , 2004, Leukemia.

[50]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[51]  E. Märker-Hermann,et al.  Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib , 2004, Annals of Hematology.

[52]  A. Tefferi,et al.  FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. , 2004, Blood.

[53]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[54]  Steven M Kornblau,et al.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. , 2004, Blood.

[55]  T. Naoe,et al.  Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. , 2004, Blood.

[56]  R. V. van Etten.  Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. , 2004, Leukemia research.

[57]  D. Gilliland,et al.  Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias , 2004, Leukemia.

[58]  Jason Gotlib,et al.  Molecular Classification and Pathogenesis of Eosinophilic Disorders: 2005 Update , 2005, Acta Haematologica.

[59]  S. Galimberti,et al.  Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. , 2005, Leukemia research.

[60]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[61]  J. Oldenburg,et al.  Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. , 2005 .

[62]  B. Quesnel,et al.  Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics , 2005, Leukemia.

[63]  H. Dombret,et al.  Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly with Imatinib Mesylate (STI571) and Chemotherapy. , 2005 .

[64]  S. Pileri,et al.  Expression of platelet-derived growth factor receptor α in peripheral T-cell lymphoma not otherwise specified , 2005 .

[65]  A. B. Lyons,et al.  Inhibition of c-fms by Imatinib: Expanding the Spectrum of Treatment , 2005, Cell cycle.

[66]  P. Marynen,et al.  The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. , 2005, Haematologica.

[67]  G. Ledderose,et al.  Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines , 2005 .

[68]  M. Baccarani,et al.  Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia , 2006, Expert opinion on biological therapy.

[69]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[70]  H. Kluin-Nelemans,et al.  Imatinib mesylate in the treatment of systemic mastocytosis , 2006, Cancer.

[71]  H. Dombret,et al.  Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials , 2006, Leukemia.

[72]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[73]  G. Lenz,et al.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .

[74]  P. Marynen,et al.  Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent , 2006 .

[75]  P. Erben,et al.  Resistance to targeted therapy in chronic myelogenous leukemia. , 2007, Seminars in hematology.

[76]  M. Baccarani,et al.  Hypereosinophilic syndrome and molecularly targeted therapy , 2007 .

[77]  U. Dührsen,et al.  Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) , 2007, Cancer.

[78]  J. Melo,et al.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. , 2007, Blood.

[79]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[80]  J. Cools,et al.  Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. , 2007, Cancer research.

[81]  M. Rondoni,et al.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.

[82]  R. Foà,et al.  Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .

[83]  M. Baccarani,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[84]  Stefano A Pileri,et al.  Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. , 2007, The Journal of clinical investigation.

[85]  R. Piazza,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[86]  H. Kantarjian,et al.  Important Therapeutic Targets in Chronic Myelogenous Leukemia , 2007, Clinical Cancer Research.

[87]  M. Baccarani,et al.  The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study , 2007, Haematologica.

[88]  P. Pilot,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[89]  P. Piccaluga,et al.  Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemia , 2007, Cancer.